BET Inhibitors (Bromodomain Inhibitors) for Neurodegenerative Diseases

Migration, Crosslink

📖

BET Inhibitors (Bromodomain Inhibitors) for Neurodegenerative Diseases

active

wiki page Created: 2026-04-02T07:19:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-bet-inhibitors-neurode

📖 Wiki Page

therapeutic879 wordssynced 2026-04-02

BET Inhibitors (Bromodomain Inhibitors) for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">BET Inhibitors (Bromodomain Inhibitors) for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Epigenetic Therapy</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Bromodomain and Extra-Terminal (BET) proteins (BRD2, BRD3, BRD4, BRDT)</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, ALS, Stroke</td>
</tr>
<tr>
<td class="label">Stage</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Condition</td>
</tr>
<tr>
<td class="label">BMS-986158</td>
<td>Advanced Solid Tumors</td>
</tr>
<tr>
<td class="label">PLX51107</td>
<td>Advanced Solid Tumors</td>
</tr>
</table>

Bet Inhibitors (Bromodomain Inhibitors) For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

...

BET Inhibitors (Bromodomain Inhibitors) for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">BET Inhibitors (Bromodomain Inhibitors) for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Epigenetic Therapy</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Bromodomain and Extra-Terminal (BET) proteins (BRD2, BRD3, BRD4, BRDT)</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, ALS, Stroke</td>
</tr>
<tr>
<td class="label">Stage</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Condition</td>
</tr>
<tr>
<td class="label">BMS-986158</td>
<td>Advanced Solid Tumors</td>
</tr>
<tr>
<td class="label">PLX51107</td>
<td>Advanced Solid Tumors</td>
</tr>
</table>

Bet Inhibitors (Bromodomain Inhibitors) For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

Mermaid diagram (expand to render)

BET (bromodomain and extra-terminal) inhibitors are a class of epigenetic drugs that block the binding of BET proteins to acetylated histone residues. By inhibiting BET proteins, these compounds prevent the transcription of pro-inflammatory genes and can modulate protein aggregation pathways relevant to neurodegenerative diseases. [@bet2019]

Mechanism of Action

BET inhibitors exert neuroprotective effects through multiple mechanisms:

Transcriptional Suppression: BET proteins are readers of histone acetylation that recruit transcriptional co-activators. Inhibiting BET proteins suppresses expression of inflammatory genes including [NF-κB](/entities/nf-kb) target genes.

[α-Synuclein](/proteins/alpha-synuclein) Regulation: BET inhibitors reduce α-synuclein expression at the transcriptional level by affecting the SNCA gene promoter.

[Tau](/proteins/tau) Pathology: BRD4 regulates [tau](/proteins/tau) expression and alternative splicing; BET inhibitors reduce tau burden in models.

Neuroinflammation: Strong anti-inflammatory effects in [microglia](/entities/microglia) and [astrocytes](/entities/astrocytes).

[Autophagy](/entities/autophagy) Induction: Some BET inhibitors activate transcription factor EB (TFEB), enhancing autophagy and lysosomal biogenesis.

Key Drug Candidates

First-Generation BET Inhibitors

JQ1: Prototype BET inhibitor; extensively studied in neurodegeneration models; shows neuroprotection in AD, PD, HD models
I-BET151 (GSK1210151A): Preclinical studies in PD and HD models
I-BET762 (GSK525762): In clinical trials for cancer; preclinical neuroprotection

Second-Generation BET Inhibitors

ABBV-744: Selective BRD4 inhibitor; better safety profile
BMS-986158: BRD4 inhibitor in clinical trials; potential for neurodegeneration
OTX015: Multiple preclinical studies in neurodegeneration

BRD4-Selective Inhibitors

AZD5153: Dual BRD4 inhibitor; improved brain penetration
PLX51107: BRD4 inhibitor with anti-inflammatory properties

Disease-Specific Applications

Alzheimer's Disease

JQ1 reduces [Aβ](/proteins/amyloid-beta) production by modulating [BACE1](/entities/bace1) expression
BET inhibitors reduce tau pathology through transcriptional regulation
Improve cognitive deficits in AD mouse models
Suppress neuroinflammation in [microglia](/cell-types/microglia-neuroinflammation)

Parkinson's Disease

I-BET151 protects dopaminergic [neurons](/entities/neurons) in MPTP models
Reduce α-synuclein expression and aggregation
Decrease neuroinflammation in PD models
BRD4 inhibition reduces LRRK2-associated toxicity

Huntington's Disease

JQ1 and I-BET151 reduce mutant [huntingtin](/proteins/huntingtin-protein) (mHTT) expression
Improve motor function and survival in HD models
Suppress transcriptional dysregulation caused by mHTT
Enhance autophagy to clear mHTT aggregates

ALS

BET inhibitors reduce SOD1 and [TDP-43](/proteins/tdp-43) aggregation
Suppress inflammatory response in ALS models
Improve survival in preclinical studies

Stroke and TBI

Post-stroke treatment with JQ1 reduces infarct size
Anti-inflammatory effects protect neurons after traumatic brain injury

Clinical Trials

Note: No clinical trials specifically for neurodegeneration as of 2024

Adverse Effects

Common side effects include:

Thrombocytopenia (dose-limiting)
Fatigue, nausea
Weight loss
Gastrointestinal effects
Second-generation inhibitors show improved safety profiles

Research Directions

Brain Penetration: Developing BET inhibitors that effectively cross the [blood-brain barrier](/entities/blood-brain-barrier)

Selectivity: Creating BRD4-selective inhibitors to reduce hematological toxicity

Combination Therapy: Combining with other disease-modifying agents

Peripheral Targeting: Targeting peripheral BET for neuroinflammation without CNS penetration

External Links

[BET Inhibitors Research - Nature Chemical Biology](https://www.nature.com/nchembio/)
[Epigenetic Therapy in Neurology](https://journals.sagepub.com/)
[ClinicalTrials.gov - BET Inhibitors](https://clinicaltrials.gov/search?cond=neurodegeneration&intr=BET)
[Alzheimer's Research UK](https://www.alzheimersresearchuk.org/)
[Parkinson's Foundation](https://www.parkinson.org/)

Background

The study of Bet Inhibitors (Bromodomain Inhibitors) For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

[^1] Nocturne G, et al, BET protein inhibition reduces alpha-synuclein pathology in Parkinson's disease models (2020)

[^2] Yin Z, et al, JQ1, a BET inhibitor, attenuates tau pathology and cognitive deficits in Alzheimer's disease models (2018)

[^3] T. Shioda et al., BET inhibitor JQ1 modulates mutant huntingtin expression and pathology in Huntington's disease models. Proc Natl Acad Sci USA. 2016;113(52):10488-10497 (2016)

[^4] Wu M, et al, I-BET151 protects dopaminergic neurons from neurotoxicity via autophagy regulation (2021)

[^5] Liu Y, et al, BRD4 regulates neuroinflammation in Alzheimer's disease via NF-κB signaling (2022)

[^6] Park G, et al, BET inhibitors attenuate microglial activation and ameliorate cognitive deficits in AD models (2021)

[^7] Cheng J, et al, BRD4 regulates alternative splicing of tau in Alzheimer's disease (2021)

[^8] H. Zhang et al., BET inhibition as a therapeutic strategy for ALS. Ann Neurol. 2019;86(4):519-531 (2019)

📖 View canonical wiki page →

Related Entities

therapeutics-bet-inhibitors-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-bet-inhibitors-neurodegeneration
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-b9a1c7083d52
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-bet-inhibitors-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

178

Outgoing

202

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

BET Inhibitors (Bromodomain Inhibitors) for Neurodegenerative Diseases

BET Inhibitors (Bromodomain Inhibitors) for Neurodegenerative Diseases

Introduction

Overview

BET Inhibitors (Bromodomain Inhibitors) for Neurodegenerative Diseases

Introduction

Overview

Mechanism of Action

Key Drug Candidates

First-Generation BET Inhibitors

Second-Generation BET Inhibitors

BRD4-Selective Inhibitors

Disease-Specific Applications

Alzheimer's Disease

Parkinson's Disease

Huntington's Disease

ALS

Stroke and TBI

Clinical Trials

Adverse Effects

Research Directions

See Also

External Links

Background

Allen Brain Atlas Resources

References

💬 Discussion